<DOC>
	<DOCNO>NCT00212290</DOCNO>
	<brief_summary>The purpose study examine effect treat insulin resistance memory attention , brain glucose utilization , proteins spinal fluid .</brief_summary>
	<brief_title>Insulin Resistance Central Nervous System ( CNS ) Function Type 2 Diabetes</brief_title>
	<detailed_description>Insulin resistant condition impair glucose tolerance , type 2 diabetes mellitus , hyperinsulinemia associate increase risk memory decline Alzheimer 's disease . The main study determine whether treatment pioglitazone nateglinide improve verbal memory selective attention old adult impair glucose tolerance mild type 2 diabetes . The main study also characterize change blood concentration insulin , inflammatory marker , beta-amyloid peptide related Alzheimer 's disease . In one sub-study , participant undergo brain positron emission tomography ( PET ) image 16 week treatment pioglitazone , nateglinide , placebo . The purpose sub-study determine effect treatment brain glucose utilization . In second sub-study , participant undergo lumbar puncture procedure treatment . The purpose sub-study determine effect treatment spinal fluid concentration insulin , inflammatory marker , beta-amyloid peptide . Together main sub-studies characterize effect insulin resistance cognition suggest mechanism insulin resistant condition increase risk memory decline Alzheimer 's disease .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Impaired glucose tolerance OR mild type 2 diabetes mellitus OR normal blood sugar regulation Stable weight activity level Medications diabetes Dementia Medications known effect memory Serious neurologic disease head trauma Serious systemic illness ( e.g. , renal failure uncontrolled hypertension ) Serious psychiatric illness ( e.g. , schizophrenia bipolar disorder ) Allergy pioglitazone nateglinide</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>impaired glucose tolerance</keyword>
</DOC>